Zhang Vertigo Treatment™
The Zhang Vertigo Treatment™ is a new medication for treating chronic, recurring vertigo associated with Ménière’s Disease, migraines, post-concussion syndrome, and other inner ear diseases. Lamotrigine (a generic anti-seizure medication) when combined with Bupropion (a generic anti-depression medication) can be manufactured as a new brand medication for use in a variety of therapies to treat chronic dizziness/vertigo. This combination could be produced as a branded medication for vertigo treatment.
PRODUCT FEATURES & BENEFITS
- Only medication for chronic recurring vertigo
- Can be manufactured as a generic medication
- Low cost to manufacture
- Combination of lamotrigine and bupropion offers better results
- Short time until this can be on the market
- Studies conducted with verifiable, positive results
Zhang Vertigo Treatment™ is a new combination drug specifically created for treating chronic recurrent vertigo. This is a debilitating condition that is often associated with Ménière’s Disease, migraines, post-concussion syndrome, and other inner-ear diseases. Although there is no cure for the vertigo, this new drug offers a better treatment.
Lamotrigine and bupropion are being considered as a new combination medication for this treatment. The pharmaceutical compositions are intended to alleviate dizziness and/or vertigo associated with Ménière’s Disease and other inner-ear diseases.
Ménière’s Disease (MD) affects more than 600,000 people in the United States and there currently is no FDA-approved treatment. Two experiments were conducted to test the effectiveness of lamotrigine for treating vertigo which showed statistical significance in reducing the number of attacks when using lamotrigine. This result indicates that lamotrigine may be an effective prophylactic treatment for vertigo attacks associated with MD.
The Zhang Vertigo Treatment™ is covered by United States Utility Patent: 9,814,723
For additional information, licensing opportunities, and a full prospectus on the Zhang Vertigo Treatment™ contact:
VP of Business Development